Tempus announced a distribution agreement to provide Predicta Biosciences’ GenoPredicta whole-genome sequencing-based assay for multiple myeloma. GenoPredicta is intended to identify actionable DNA alterations, stratify high-risk patients, and support monitoring for minimal residual disease. Tempus said GenoPredicta can be run on both peripheral blood and bone marrow samples and is built to replace a set of siloed tests by combining flow cytometry, cytogenetics, and WGS into one workflow. The company described the assay as ultra-sensitive, including from as few as 50 tumor cells. For clinical programs in myeloma, broader distribution of WGS-based MRD-adjacent tools may improve both risk characterization and longitudinal monitoring as precision regimens evolve.